Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse

Nature Medicine

Volumn 9, Issue 8, 2003, Pages 1009-1014

  Lu, Qi Long ^a   Mann, Christopher J ^b   Lou, Fang ^c   Bou Gharios, George ^a   Morris, Glenn E ^d   Xue, Shao An ^e   Fletcher, Sue ^b   Partridge, Terence A ^a   Wilton, Stephen D ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b PATHWEST LABORATORY MEDICINE   (Australia)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^d GLYNDWR UNIVERSITY   (United Kingdom)

^e Faculty of Medicine   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGORIBONUCLEOTIDE 2 O METHYL PHOSPHOROTHIOATE; DYSTROPHIN; OLIGORIBONUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; AGING; ALTERNATIVE RNA SPLICING; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; GENE; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC TRANSFECTION; MDX GENE; MOUSE; MUSCLE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TECHNIQUE;

ANIMALS; DYSTROPHIN; EXONS; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; MUSCULAR DYSTROPHY, DUCHENNE; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; RNA SPLICING;

ANIMALIA;

EID: 0042536463     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm897     Document Type: Article

References (26)

1. Hoffman, E.P., Brown, R.H. Jr. & Kunkel, L.M. Oystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928 (1987).
2. Laing, N.G. Molecular genetics and genetic counselling for Duchenne/Becker muscular dystrophy, in Molecular and Cell Biology of Muscular Dystrophy (ed. Partridge, T.) 37-84 (Chapman & Hall, London, 1993).
3. Beauchamp, J.R., Morgan, J.E., Pagel, C.N. & Partridge, T.A. Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source. J. Cell. Biol. 144, 1113-1122 (1999).
4. Liu, F., Nishikawa, M., Clemens, P.R. & Huang, L. Transfer of full-length Dmd to the diaphragm muscle of Dmd(mdx/mdx) mice through systemic administration of plasmid DNA. Mol. Ther. 4, 45-51 (2001).
5. Yuasa, K. et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 9, 1576-1588 (2002).
6. Wang, B., Li, J. & Xiao, X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA. 97, 13714-13719 (2000).
7. Monaco, A.P. et al. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-95 (1988).
8. Mann, C.J. et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. USA. 98, 42-47 (2001).
9. Dickson, G., Hill, V. & Graham I.R. Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul. Disord. 12 (suppl. 1), S67-S70 (2002).
10. Aartsma-Rus, A. et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12 (suppl. 1), S71-S77 (2002).
11. Lu, Q.L., Bou-Gharios, G. & Partridge, T.A. Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. 10, 131-142 (2003).
12. Lu, Q.L. et al. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J. Cell Biol. 148, 985-996 (2000).
13. Watchko, J. et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 13, 1451-1460 (2002).
14. Rando, T.A., Disatnik, M.H. & Zhou, L.Z. Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. Proc. Natl. Acad. Sci. USA 97, 5363-5368 (2000).
15. Wagner, K.R. et al. Gentamycin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann. Neurol. 49, 706-711 (2001).
16. England, S.B. et al. Very mild muscular dystrophy associated with deletion of 40% dystrophin. Nature 343, 180-182 (1990).
17. Sherratt, T.G. et al. Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am. J. Hum. Genet. 53, 1007-1015 (1993).
18. Wilton, S.D. et al. Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul. Disord. 7, 329-335 (1997).
19. Dominski, Z. & Kole, R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 90, 8673-8677 (1993).
20. De Angelis, F.G. et al. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells. Proc. Natl. Acad. Sci. USA 99, 9456-9461 (2002).
21. Mann, C.J. et al. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med 4, 644-654 (2002).
22. Sazani, P. et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228-1233 (2002).
23. Lu, Q.L. & Partridge, T.A. A new blocking method for application of murine monoclonal antibody to mouse tissue sections. J. Histochem. Cytochem. 46, 977-984 (1998).
24. Lu, QL., Liang, H.D., Partridge, T. & Blomley, M.J. Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther. 10, 396-405 (2003).
25. Lou, F., Curtin, N.A. & Woledge, R.C. Isometric and isovelocity contractile performance of red muscle fibres from the dogfish Scyliorhinus canicula. J. Exp. Biol. 205, 1585-1595 (2002).
26. Lynch, G.S. et al. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J. Physiol. 535, 591-600 (2001).